Quantitative assessment of radioactivity losses in the administration of therapeutic doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE
Nuclear Medicine Review · 2024
DOI: 10.5603/nmr.102682 ↗At a glance
Journal article in Nuclear Medicine Review, 2024. Written by Izabela Cieszykowska and 9 co-authors. Institution: Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland. izabela.cieszykowska@polatom.pl. Major MEDLINE topics: Octreotide, Organometallic Compounds. Cited 3 times so far (Crossref).
Abstract (original language)
Background
Therapeutic radiopharmaceuticals [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE are used in peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. One of the factors determining the efficacy of such therapy is administering the radiopharmaceutical dose to the patients in a way consistent with treatment planning. This paper evaluates the loss of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE and their mixed doses during the administration to the patient either by direct infusion or by gravity method. Material and methods: The loss of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE, was assessed in tests simulating the administration procedures and during infusion to the patients performed at four clinical centres. One clinical centre used a direct infusion, and three others used a gravity method to administer radiopharmaceuticals to the patient.
Results
In the direct infusion the highest radioactivity loss was 3.88% ± 0.49% (n = 3) and 3.76% ± 0.83% (n = 3) for [177Lu] Lu-DOTA-TATE infusion with radioactivity of 3.71 GBq ± 0.08 GBq (n = 3) and 1.06 GBq ± 0.08 GBq (n = 3), respectively, and 4.04% ± 0.40% (n = 5) for infusion of [90Y]Y-DOTA-TATE dose of 1.98 GBq ± 0.05 GBq (n = 5). In the gravity method administration of [177Lu]Lu-DOTA-TATE generated losses of up to 1.31% ± 0.46% (n = 16) for a dose of 7.45 GBq ± 0.06 GBq (n = 16) and 2.93% ± 1.64% (n = 8) for a dose of 3.78 GBq ± 0.05 GBq (n = 8). However, the infusion of the lowest doses of 0.95 GBq ± 0.01 GBq (n = 4) [177Lu]Lu-DOTA-TATE and 1.96 GBq ± 0.03 GBq (n = 8) [90Y]Y-DOTA-TATE resulted in higher loss of radiopharmaceuticals up to 6.00% ± 0.97% (n = 4) and 4.00% ± 1.57% (n = 8), respectively.
Conclusions
Both investigated methods of radiopharmaceutical administration are associated with the loss of the radioactivity of radiopharmaceutical.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland. izabela.cieszykowska@polatom.pl.
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.
- Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Military Institute of Medicine - National Research Institute, Warsaw, Poland.
- Holy Cross Cancer Center, Kielce, Poland.
- Jagiellonian University Medical College, Kraków, Poland.
ORCID profiles: Izabela Cieszykowska, Tomasz Janiak, Małgorzata Żółtowska, Renata Mikołajczak, Piotr Garnuszek
Cite
APA
Cieszykowska, I., Rybak, P., Janiak, T., Żółtowska, M., Ochman, P., Steczek, Ł., Szczodry, A., Lenda-Tracz, W., Mikołajczak, R., & Garnuszek, P. (2024). Quantitative assessment of radioactivity losses in the administration of therapeutic doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE. Nuclear Medicine Review. https://doi.org/10.5603/nmr.102682
Vancouver
Cieszykowska I, Rybak P, Janiak T, Żółtowska M, Ochman P, Steczek Ł, et al. Quantitative assessment of radioactivity losses in the administration of therapeutic doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE. Nuclear Medicine Review. 2024. doi:10.5603/nmr.102682
BibTeX
@article{Cieszykowska2024,
author = {Cieszykowska, Izabela and Rybak, Paweł and Janiak, Tomasz and Żółtowska, Małgorzata and Ochman, Paweł and Steczek, Łukasz and Szczodry, Artur and Lenda-Tracz, Wioletta and Mikołajczak, Renata and Garnuszek, Piotr},
title = {Quantitative assessment of radioactivity losses in the administration of therapeutic doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE},
journal = {Nuclear Medicine Review},
year = {2024},
doi = {10.5603/nmr.102682}
}
EUVIMED